The estimated Net Worth of Moltke Lisa Von is at least $23.1 Mille dollars as of 15 August 2024. Lisa Von owns over 2,969 units of Seres Therapeutics Inc stock worth over $23,085 and over the last 4 years he sold MCRB stock worth over $0. In addition, he makes $0 as Executive Vice President e Chief Medical Officer at Seres Therapeutics Inc.
Sign up
Lisa Moltke MCRB stock SEC Form 4 insiders trading
Lisa has made over 4 trades of the Seres Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 2,969 units of MCRB stock worth $3,117 on 15 August 2024.
The largest trade he's ever made was exercising 13,745 units of Seres Therapeutics Inc stock on 27 October 2023 worth over $14,432. On average, Lisa trades about 2,869 units every 27 days since 2020. As of 15 August 2024 he still owns at least 21,986 units of Seres Therapeutics Inc stock.
You can see the complete history of Lisa Von stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lisa von Moltke biography
Dr. Lisa von Moltke M.D. serves as Executive Vice President, Chief Medical Officer of the Company. She has served as our Executive Vice President and Chief Medical Officer since March 2020. Previously, Dr. von Moltke worked for Alkermes, Inc., a pharmaceutical company, since June 2015, where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development from June 2015 to December 2019. Beginning in June 2015, Dr. Moltke served as VP Clinical Pharmacology, DMPK and Bioanalytics, was promoted to Head of Clinical Development in November 2015, and became SVP in June 2018. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, a biotechnology company, from 2009 to 2015 and was US Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development. Starting in 2014 she was Head CEP for Japan and China regions. From 2006 to 2009, Dr. von Moltke was Head, Translational Medicine for the Takeda Oncology Company, a biopharmaceutical company in Cambridge, MA. She has served as President of the American College of Clinical Pharmacology, and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned a Bachelors of Arts degree at Wellesley College and her Doctor of Medicine from Michigan State University, College of Human Medicine.
How old is Lisa Moltke?
Lisa Moltke is 61, he's been the Executive Vice President e Chief Medical Officer of Seres Therapeutics Inc since 2020. There are 7 older and 13 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
What's Lisa Moltke's mailing address?
Moltke's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Seres Therapeutics Inc
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... e Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
What does Seres Therapeutics Inc do?
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
What does Seres Therapeutics Inc's logo look like?
Complete history of Lisa Von stock trades at Cara Therapeutics Inc e Seres Therapeutics Inc
Seres Therapeutics Inc executives and stock owners
Seres Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Eric Shaff,
President, Chief Executive Officer, Director -
Eric D. Shaff M.B.A.,
Pres, CEO & Director -
Thomas DesRosier,
Chief Legal Officer, Executive Vice President and Secretary -
Matthew Henn,
Executive Vice President, Chief Scientific Officer -
Thomas J. DesRosier,
Chief Legal Officer, Exec. VP & Sec. -
Dr. David S. Ege Ph.D.,
Exec. VP & Chief Technology Officer -
Richard Kender,
Independent Director -
Kurt Graves,
Independent Director -
Meryl Zausner,
Independent Director -
Willard Dere,
Independent Director -
Gregory Behar,
Independent Director -
Dennis Ausiello,
Independent Director -
Stephen Berenson,
Independent Chairman of the Board -
David Ege,
Executive Vice President, Chief Technology Officer -
Jayne Gansler,
Chief People Officer, Executive Vice President -
Terri Young,
Executive Vice President, Chief Commercial and Strategy Officer -
Lisa von Moltke,
Executive Vice President, Chief Medical Officer -
Paul Biondi,
Independent Director -
Carlo Tanzi,
Head of Investor Relations and Corporate Communications -
John Aunins,
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer -
Marcus Chapman,
Senior Vice President - Finance and Principal Financial and Accounting Officer -
Dr. John G. Aunins Ph.D.,
Sr. Advisor -
Dr. Matthew R. Henn Ph.D.,
Exec. VP & Chief Scientific Officer -
David A. Arkowitz M.B.A.,
Exec. VP, CFO & Head of Bus. Devel. -
James R. Weston,
Sr. VP of Regulatory Affairs -
Jayne M. Gansler,
Exec. VP & Chief People Officer -
Jeff York,
VP of HR -
Noubar Flagship Ventures Fu...,
-
Peter Barton Hutt,
Director -
Michele Trucksis,
See Remarks -
David N Cook,
See Remarks -
Noubar Afeyan,
Director -
Health Science Us Holdings,...,
-
Lorence H. Kim,
Director -
Wael Hashad,
EVP & Chief Commercial Officer -
Teresa L. Young,
See Remarks -
Paula Cloghessy,
See Remarks -
Marella Thorell,
See Remarks -
Roger Pomerantz,
President and CEO -
Kevin Horgan,
Chief Medical Officer and EVP -
Werner Cautreels,
Director -
Noubar Flagship Ventures Fu...,
-
Ventures Fund Iv General Pa...,
-
Health Ltp Fund General Par...,
-
David Arkowitz,
Chief Financial Officer -
Health Ltp Fund General Par...,
-
Claire Fraser,